OpenLegislation

Regulation 16 Amendment of regulation 2

Original text. Later amendments are not shown.

Regulation 2(1)f1 (interpretation), at the appropriate places in the alphabetical order insert—

  • ““EAMS medicinal product” means a medicinal product that—

    1. (a)

      has been included in the Early Access to Medicines Scheme by means of the licensing authority issuing an EAMS scientific opinion in respect of it; and

    2. (b)

      remains in the scheme by virtue of the EAMS scientific opinion not ceasing to have effect in respect of it by virtue of regulation 167D of the 2012 Regulations;”;

  • ““EAMS scientific opinion” is to be construed in accordance with regulation 167C(2)(b) of the 2012 Regulations;”; and

  • ““Early Access to Medicines Scheme” means the scheme of that name established and operated under regulation 167C(1) of the 2012 Regulations;”.

Annotations

Footnotes

f1

Amended by S.I. 2004/3224, 2006/562 and 1928, 2007/3101, 2008/941, 2010/231, 2011/2581, 2012/1641 and 1916, 2013/235, 2016/696, and 2019/593, 744 and 1094, and by S.R. 2008 No. 192.